---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Afamitresgene Autoleucel - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/afamitresgene-autoleucel
version: v1
---

# Afamitresgene Autoleucel - NCI

# Afamitresgene Autoleucel

Placeholder slot

(A-fam-ih-TRES-jeen AW-toh-LOO-sel)

Afamitresgene autoleucel uses a patient's T cells (a type of immune system cell). In the lab, a special receptor is added to the T cells, allowing them to recognize an antigen (protein) called MAGE-A4, found on some cancer cells. These modified T cells are then grown in large numbers in the lab and infused back into the patient. Once inside the body, afamitresgene autoleucel binds to the MAGE-A4 antigen on cancer cells, helping the immune system to attack and kill the cancer cells. This treatment is a type of cellular immunotherapy called T-cell receptor therapy.

US Brand Name(s)

Tecelra

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab24631f-3364-46e1-8074-7244863bcbab&audience=consumer)

## Use in Cancer

Afamitresgene autoleucel
is approved to treat adults with:

- **[synovial sarcoma](/Common/PopUps/popDefinition.aspx?id=44626&version=Patient&language=English)** that has spread to other parts of the body or cannot be removed by surgery. It is used in patients who have received chemotherapy, who have the blood [antigens](/Common/PopUps/popDefinition.aspx?id=46086&version=Patient&language=English) [HLA-A\*02:01P](/Common/PopUps/popDefinition.aspx?id=809232&version=Patient&language=English), HLA-A\*02:02P, HLA-A\*02:03P, or HLA-A\*02:06P, and whose cancer has the MAGE-A4 antigen.

Afamitresgene autoleucel is approved under FDAâ€™s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that it provides a clinical benefit in these patients.

Afamitresgene autoleucel
is also being studied in the treatment of other types of
cancer.

## More About Afamitresgene Autoleucel

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/790617) - Detailed scientific definition and other names for this drug.

## Research Results and Related Resources

[FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma](https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Immunotherapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Afamitresgene Autoleucel](https://www.cancer.gov/research/participate/clinical-trials/intervention/C175738) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
